International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Danne, Thomas, Garg, Satish, Peters, Anne L., Buse, John B., Mathieu, Chantal, Pettus, Jeremy H., Alexander, Charles M., Battelino, Tadej, Ampudia-Blasco, F. Javier, Bode, Bruce W., Cariou, Bertrand, Close, Kelly L., Dandona, Paresh, Dutta, Sanjoy, Ferrannini, Ele, Fourlanos, Spiros, Grunberger, George, Heller, Simon R., Henry, Robert R., Kurian, Martin J., Kushner, Jake A., Oron, Tal, Parkin, Christopher G., Pieber, Thomas R., Rodbard, Helena W., Schatz, Desmond, Skyler, Jay S., Tamborlane, William V., Yokote, Koutaro, Phillip, Moshe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Consensus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973545/
https://www.ncbi.nlm.nih.gov/pubmed/30728224
http://dx.doi.org/10.2337/dc18-2316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973545/
https://www.ncbi.nlm.nih.gov/pubmed/30728224
http://dx.doi.org/10.2337/dc18-2316

Ejemplares similares